Amphista Therapeutics - Gilde Healthcare

Amphista Therapeutics

Venture&Growth
Location
Glasgow, Scotland
Targeted Protein Degradation
Since: 2021
Venture&Growth

Amphista Therapeutics is a UK-based biopharmaceutical company creating first-in-class therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins.

The company’s next generation targeted protein degradation (TPD)-based medicines use a novel set of mechanisms that make use of a wider range of the body’s own innate protein degrading proteins, instead of the very narrow set of ubiquitin E3 ligase-based mechanisms used by most other TPD companies. This proprietary approach offers the potential to overcome many of the limitations seen with current TPD approaches, providing the opportunity to treat a wider range of diseases, including cancer.

Amphista Therapeutics raised a $53 million (£38 million) Series B financing co-led by Gilde Healthcare to further develop its differentiated TPD platform and bring drug candidates to the clinic.

More Amphista Therapeutics news

Amphista Therapeutics announces in vivo efficacy and CNS activity of its protein degraders

Gilde Healthcare company Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Gilde Healthcare company Amphista Therapeutics enters a up to $1.25 billion strategic collaboration with Bristol Myers Squibb

Gilde Healthcare company Amphista Therapeutics appoints new chairman, Joshua T. Brumm

Amphista Therapeutics raises $53M in Series B round co-led by Gilde Healthcare to advance next generation targeted protein degradation assets